Compare CNDT & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | NKTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | 51000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4M | 227.4M |
| IPO Year | 2016 | 2020 |
| Metric | CNDT | NKTX |
|---|---|---|
| Price | $1.38 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,042,000,000.00 | N/A |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $1.63 |
| 52 Week High | $2.98 | $3.65 |
| Indicator | CNDT | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 44.32 |
| Support Level | $1.33 | $2.59 |
| Resistance Level | $1.60 | $2.78 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 10.37 | 12.42 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.